3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
35
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Myelodysplastic Syndromes
19
Lymphoma, Non-Hodgkin
11
Hodgkin Disease
10
Leukemia, Biphenotypic, Acute
8
Multiple Myeloma
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Leukemia
7
Burkitt Lymphoma
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Myeloproliferative Disorders
6
Neuroblastoma
5
Lymphoma, Mantle-Cell
5
Lymphoma, Large B-Cell, Diffuse
5
Anemia, Refractory, with Excess of Blasts
5
Recurrence
4
Lymphoma
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Hematologic Neoplasms
4
Breast Neoplasms
4
Lymphoma, T-Cell
3
Lymphoma, Follicular
3
Leukemia, Myelomonocytic, Chronic
3
Sarcoma
2
Rhabdomyosarcoma
2
Primary Myelofibrosis
2
Neoplasms, Plasma Cell
2
Myelodysplastic-Myeloproliferative Diseases
2
Medulloblastoma
2
Interventions
pembrolizumab
96
Carboplatin
67
Paclitaxel
56
Cyclophosphamide
40
Capecitabine
30
Specimen Handling
28
sacituzumab govitecan
25
130-nm albumin-bound paclitaxel
24
Gemcitabine
22
Magnetic Resonance Spectroscopy
21
Doxorubicin
20
olaparib
19
Taxes
19
Biopsy
19
Albumin-Bound Paclitaxel
19
Drug Therapy
16
atezolizumab
13
Nivolumab
13
toripalimab
12
Radiotherapy
12
Epirubicin
12
durvalumab
11
Docetaxel
10
Cisplatin
10
Bevacizumab
10
eribulin
9
fludarabine
8
Standard of Care
7
Radiation
7
Injections
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Granulocyte Colony-Stimulating Factor
×
1 year
×
Clear all
NCT05520723
2025-12-04
PRIMED
MedSIR
Phase 2
Completed
50 enrolled